David A. Siegel Checkpoint Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.02 - $10.6 $72,318 - $751,540	-70,900 Reduced 46.95%	80,100 $83,000
Q2 2022 Aug 15, 2022	SELL	$0.97 - $1.77 $101,559 - $185,319	-104,700 Reduced 40.95%	151,000 $156,000
Q1 2022 May 16, 2022	SELL	$1.53 - $3.25 $19,890 - $42,250	-13,000 Reduced 4.84%	255,700 $453,000
Q4 2021 Feb 14, 2022	SELL	$2.68 - $4.46 $409,236 - $681,042	-152,700 Reduced 36.24%	268,700 $836,000
Q3 2021 Nov 15, 2021	BUY	$2.5 - $3.53 $293,750 - $414,775	117,500 Added 38.66%	421,400 $1.39 Million
Q2 2021 Aug 16, 2021	BUY	$2.36 - $3.2 $109,032 - $147,840	46,200 Added 17.93%	303,900 $897,000
Q1 2021 May 17, 2021	BUY	$2.6 - $4.16 $624,780 - $999,648	240,300 Added 1381.03%	257,700 $809,000
Q4 2020 Feb 16, 2021	BUY	$2.19 - $2.96 $38,106 - $51,504	17,400 New	17,400 $46,000

1.91M

Ticker CKPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,497,000
Market Cap $234M
Description
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.